secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001157523-24-000230
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra Therapeutics presents at Oppenheimer Healthcare Conference; no material new financial data disclosed
--------------------------------------------------------------------------------

- CEO Todd Brady participates virtually in fireside chat at Oppenheimer 34th Annual Healthcare Life Sciences Conference on Feb 13, 2024.
- Discussion covers clinical and regulatory status of Aldeyra's product candidates for immune-mediated diseases.
- Corporate presentation furnished as Exhibit 99.1; no earnings or financial guidance provided.
- Filing is Regulation FD disclosure; presentation not incorporated by reference.
- No specific milestones, data readouts, or financial results announced in the exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752324000230/0001157523-24-000230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752324000230/a53895165.htm
  HTML page:      https://secwatch.observer/filing/0001157523-24-000230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer